Document is current
Any future updates will be listed below
-
Authors
Sra, Manraj Singh https://orcid.org/0000-0002-2939-5400
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
- License Information
-
More Information
Article History
Received: 10 March 2026
Revised: 16 April 2026
Accepted: 22 May 2026
First Online: 29 May 2026
Competing interests
: SVR is Chair of the International Myeloma Foundation Board of Directors; has received honoraria for CME Lectures for Medscape; declares intellectual property and royalties as an author and section editor for UpToDate (covering topics on plasma cell disorders). SK has acted as a consultant or adviser (with all payments made to his institution) for AbbVie, Bristol Myers Squibb/Celgene, Genentech/Roche, Janssen Oncology/Johnson & Johnson, K36, Pfizer, Regeneron, Sanofi and Takeda; declares research funding (to his institution) from AbbVie, Allogene Therapeutics, Bristol Myers Squibb/Celgene, CARsgen Therapeutics, GlaxoSmithKline, Janssen Oncology/Johnson & Johnson, MedImmune, Novartis, Regeneron, Roche/Genentech, Sanofi and Takeda; and has received reimbursement for travel, accommodation and expenses from AbbVie, Beigene, Janssen/Johnson & Johnson and Pfizer. MSS declares no competing interests.
